Want to see AEON full AI Analyst Report?
Top Page
AEON Biopharma
(AEON)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.26
▲(5.60% Upside)
Action:Reiterated
Date:08/17/26
The score is primarily constrained by weak financial performance (no revenue, large losses, negative equity, and ongoing cash burn) and bearish technical trends (price below key moving averages with negative MACD). Valuation provides limited support given negative earnings and no dividend data.
Positive Factors
Regulatory pathway clarity
FDA feedback provides a clearer framework for completing ABP-450's analytical work. This can reduce regulatory uncertainty, focus development spending, and improve the program's ability to progress toward a potential biosimilar filing.
Negative Factors
Pre-revenue operating model
AEON has no operating revenue to offset its development costs, while losses remain substantial. Until a product reaches the market, financial performance will depend mainly on clinical and regulatory execution rather than recurring commercial demand.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory pathway clarity
FDA feedback provides a clearer framework for completing ABP-450's analytical work. This can reduce regulatory uncertainty, focus development spending, and improve the program's ability to progress toward a potential biosimilar filing.
Read all positive factors
AEON Biopharma (AEON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.72M
Dividend YieldN/A
Average Volume (3M)273.24K
Price to Earnings (P/E)―
Beta (1Y)1.12
Revenue GrowthN/A
EPS Growth35.03%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.45
Shares Outstanding49,882,790
10 Day Avg. Volume605,674
30 Day Avg. Volume273,237
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.63
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.10Price Target Upside340.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.76
Revenue Forecast (FY)N/A
AEON Biopharma Business Overview & Revenue Model
Company Description
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botuli...
How the Company Makes Money
null...
AEON Biopharma Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -39.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -25.68M | -16.22M | -27.73M | -52.74M | -52.49M | -36.88M |
| Net Income | -54.62M | -39.22M | 42.01M | -384.63M | -52.56M | -55.64M |
Balance Sheet | ||||||
| Total Assets | 5.91M | 5.56M | 3.14M | 6.84M | 10.78M | 6.44M |
| Cash, Cash Equivalents and Short-Term Investments | 3.43M | 3.01M | 13.00K | 5.16M | 9.75M | 5.13M |
| Total Debt | 2.77M | 35.74M | 12.96M | 278.00K | 131.53M | 86.89M |
| Total Liabilities | 21.27M | 60.59M | 31.71M | 159.89M | 281.19M | 230.26M |
| Stockholders Equity | -15.36M | -55.03M | -28.57M | -153.04M | -287.50M | -234.94M |
Cash Flow | ||||||
| Free Cash Flow | -13.64M | -17.31M | -20.29M | -47.83M | -35.89M | -28.60M |
| Operating Cash Flow | -13.64M | -17.31M | -20.29M | -47.83M | -35.58M | -28.43M |
| Investing Cash Flow | 0.00 | -4.00K | 0.00 | 0.00 | -306.00K | -170.00K |
| Financing Cash Flow | 8.63M | 20.30M | 15.15M | 14.00M | 40.51M | 13.56M |
AEON Biopharma Technical Analysis
Negative
0.25
Price Trends
0.49
Negative
0.70
Negative
0.86
Negative
Market Momentum
-0.06
Negative
33.95
Neutral
23.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AEON, the sentiment is Negative. The current price of 0.25 is below the 20-day moving average (MA) of 0.27, below the 50-day MA of 0.49, and below the 200-day MA of 0.86, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 33.95 is Neutral, neither overbought nor oversold. The STOCH value of 23.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AEON.
AEON Biopharma Risk Analysis
AEON Biopharma disclosed 62 risk factors in its most recent earnings report. AEON Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AEON Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $3.47M | ― | -99.39% | ― | ― | 95.40% | |
46 Neutral | $9.26M | -0.36 | -341.23% | ― | ― | 71.67% | |
42 Neutral | $13.72M | -0.05 | 223.66% | ― | ― | 35.03% | |
39 Underperform | $6.40M | -0.85 | -269.02% | ― | ― | ― |
* Healthcare Sector Average
AEON
AEON Biopharma
0.28
-0.49
-63.82%
IMNN
Imunon
1.65
-4.83
-74.54%
XTLB
XTL Biopharmaceuticals Sponsored ADR
2.79
-2.66
-48.81%
RNAZ
TransCode Therapeutics
3.28
-7.22
-68.76%
AEON Biopharma Corporate Events
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
AEON Biopharma Reports Q2 Results, Advances ABP-450 Program
Positive
Aug 12, 2026
On August 12, 2026, AEON Biopharma reported second-quarter 2026 results and a corporate update, highlighting continued progress in advancing ABP-450 through the analytical phase of its biosimilar program and preparations for further FDA regulatory...
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
AEON Biopharma Regains NYSE American Listing Compliance
Positive
Aug 3, 2026
On August 3, 2026, AEON Biopharma announced it had regained compliance with NYSE American’s continued listing standards related to stockholders’ equity, resolving deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE Ameri...
Business Operations and StrategyPrivate Placements and Financing
AEON Biopharma boosts liquidity with additional share sale
Positive
Jul 23, 2026
On July 15, 2026, AEON Biopharma, Inc. completed a public equity offering and, on July 23, 2026, sold an additional 4,696,102 shares of Class A common stock through a partial exercise of the underwriters’ over-allotment option, generating ap...
Executive/Board ChangesShareholder Meetings
AEON Biopharma shareholders approve directors and auditor slate
Positive
Jun 17, 2026
AEON Biopharma, Inc. held its Annual Meeting of Stockholders on June 17, 2026, at which shareholders elected Marc Forth and Seongsoo Park as Class III directors to serve three-year terms expiring at the 2029 annual meeting. Shareholders also ratif...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.